50
Participants
Start Date
August 13, 2024
Primary Completion Date
June 2, 2027
Study Completion Date
June 30, 2027
Pelabresib
Small molecule inhibitor of bromodomain and extraterminal (BET) protein
RECRUITING
ZNA Cadix-Hematology, Antwerp
RECRUITING
Az St-Jan Brugge-Oostende A.V., Bruges
RECRUITING
Mount Sinai Hospital - Oncology, New York
RECRUITING
Weill Cornell Medicine - New York Presbyterian Hospital (Oncology), New York
RECRUITING
AO Ospedale di Circolo, PO Varese (Ematologia), Varese
ENROLLING_BY_INVITATION
Azienda Ospedaliero - Universitaria Maggiore della Carità (SCDU Ematologia), Novara
RECRUITING
AOU Careggi (Department of Experimental and Clinical Medicine), Florence
RECRUITING
Hematologic Malignancy/Stem (Department of Medicine, Division of Hematology/Oncology), Los Angeles
RECRUITING
Mayo Clinic (Cancer Clinical Research Office), Jacksonville
RECRUITING
Northwestern Memorial Hospital (Oncology), Chicago
RECRUITING
UMHS - University of Michigan Medical Center (Radiation Oncology), Ann Arbor
RECRUITING
Amsterdam UMC location Vumc (Hematology), Amsterdam
RECRUITING
Cardiff and Vale University Health Board - University Hospital Wales (Hematology), Cardiff
RECRUITING
Beatson West of Scotland Cancer Centre (Hematology), Glasgow
RECRUITING
Guys and St Thomas' Hospital - Haematology, London
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY